4.1. Kết luận
Từ những kết quả nêu trên, chúng tôi rút ra được những kết luận như sau: 1- Chúng tơi đã giải mã thành cơng trình tự ADN của các gen fiber, penton và hexon của chủng HAdV-3 gây bệnh đau mắt đỏ ở Việt Nam. Tổng chiều dài các gen nêu trên lần lượt là 960 bp, 1635 bp, và 2835 bp.
2- Chúng tôi đã phát hiện được những biển đổi trong trình tự ADN của các gen nêu trên so với trình tự tham chiếu trên thế giới. Các biển đổi này được dự đoán là dẫn tới những biến đổi axit amin của protein tương ứng. Cụ thể, 3 gen fiber, penton, và hexon có lần lượt 15, 24, và 42 biển đổi trên trình tự ADN. Ba protein tương ứng có lần lượt 10, 5, và 11 biến đổi axit amin. Những tính tốn về tỉ lệ cho thấy, gen và protein fiber dường như có tỉ lệ biển đổi ADN cao nhất và tỉ lệ biến đổi axit amin cũng cao nhất. Trong khi đó, penton ln là gen/protein có tỉ lệ thấp nhất ở các tiêu chí này.
3- Cả 3 protein fiber, penton, và hexon được dự đốn có những biến đổi tiềm ẩn nguy cơ cao gây hại cho con người. Cụ thể, các biến đổi axit amin ở protein fiber có nguy cơ làm thay đổi sự tương tác của protein này với thụ thể CD46 ở bệnh nhân. Ở protein penton, các biến đổi có khả năng cao làm tăng khả năng xâm nhiễm và độc lực của vi-rút. Còn đối với hexon, các biến đổi lại mang đến nguy cơ giúp vi-rút lẩn trốn khỏi hệ miễn dịch và tăng cường sức sống.
4.2. Kiến nghị
Chúng tôi xin kiến nghị hàng năm thực hiện phân tích các biến đổi ở 3 gen fiber, penton, và hexon của HAdV-3 nói riêng và các chủng HAdV gây bệnh đau mắt đỏ ở Việt Nam nói chung. Việc làm này là rất cần thiết để theo dõi q trình tiến hóa của loại vi-rút này, từ đó giúp chúng ta tìm cách phịng tránh và điều trị bệnh hiệu quả.
TÀI LIỆU THAM KHẢO
1. Al-Haggar, M., et al. (2012), "A novel homozygous p.Arg527Leu LMNA mutation in two unrelated Egyptian families causes overlapping mandibuloacral dysplasia and progeria syndrome", Eur J Hum Genet, 20(11): pp. 1134-40.
2. Allawi, H.T. and J. SantaLucia, Jr. (1997), "Thermodynamics and NMR of internal G.T mismatches in DNA", Biochemistry, 36(34): pp. 10581-94. 3. Avissar, Y., et al.(2018), "Biology: OpenStax".pp 91.
4. Azari, A.A. and N.P. Barney (2013), "Conjunctivitis: a systematic review of diagnosis and treatment", JAMA, 310(16): pp. 1721-9.
5. Bergelson, J.M., et al. (1997), "Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5", Science, 275(5304): pp. 1320-3.
6. Berk, A.J.(2007), "Fields virology", 5th ed. Vol. 2, Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins.pp
7. Buckwalter, S.P., et al. (2012), "Real-time qualitative PCR for 57 human adenovirus types from multiple specimen sources", J Clin Microbiol, 50(3): pp. 766-71.
8. Burnett, R.M. (1985), "The structure of the adenovirus capsid. II. The packing symmetry of hexon and its implications for viral architecture", J Mol Biol,
185(1): pp. 125-43.
9. Burnett, R.M., M.G. Grutter, and J.L. White (1985), "The structure of the adenovirus capsid. I. An envelope model of hexon at 6 A resolution", J Mol
Biol, 185(1): pp. 105-23.
10. Chothia, C. and A.M. Lesk (1986), "The relation between the divergence of sequence and structure in proteins", EMBO J, 5(4): pp. 823-6.
11. Clancy, S. (2008), "Genetic Mutation", Nature Education, 1(1): pp. 187. 12. Collins, F.S., M.S. Guyer, and A. Charkravarti (1997), "Variations on a theme:
13. Cupelli, K., et al. (2010), "Structure of adenovirus type 21 knob in complex with CD46 reveals key differences in receptor contacts among species B adenoviruses", J Virol, 84(7): pp. 3189-200.
14. DeLano, W.L. (2002), "The PyMOL Molecular Graphics System, Educationnal Version Schrödinger, LLC",
15. Durmort, C., et al. (2001), "Structure of the fiber head of Ad3, a non-CAR- binding serotype of adenovirus", Virology, 285(2): pp. 302-12.
16. Erdman, D.D., et al. (2002), "Molecular epidemiology of adenovirus type 7 in the United States, 1966-2000", Emerg Infect Dis, 8(3): pp. 269-77.
17. Fender, P., et al. (2012), "Impact of human adenovirus type 3 dodecahedron on host cells and its potential role in viral infection", J Virol, 86(9): pp. 5380- 5.
18. Fender, P., et al. (1997), "Adenovirus dodecahedron, a new vector for human gene transfer", Nat Biotechnol, 15(1): pp. 52-6.
19. Filleul, L., et al. (2018), "Costs of Conjunctivitis Outbreak, Reunion Island, France", Emerg Infect Dis, 24(1): pp. 168-170.
20. Flomenberg, P., et al. (1995), "Characterization of human proliferative T cell responses to adenovirus", J Infect Dis, 171(5): pp. 1090-6.
21. Gaggar, A., D.M. Shayakhmetov, and A. Lieber (2003), "CD46 is a cellular receptor for group B adenoviruses", Nat Med, 9(11): pp. 1408-12.
22. Ghebremedhin, B. (2014), "Human adenovirus: Viral pathogen with increasing importance", Eur J Microbiol Immunol (Bp), 4(1): pp. 26-33. 23. Gooding, L.R. and W.S. Wold (1990), "Molecular mechanisms by which
adenoviruses counteract antiviral immune defenses", Crit Rev Immunol,
10(1): pp. 53-71.
24. Ha, N.V., et al. (2016), "Method Development for Detection and Classification of Conjunctivitis-Causing Adenoviruses in Human", VNU Journal of Science:
25. Hall, T.A. (1999), "BioEdit: A User-Friendly Biological Sequence Alignment Editor and Analysis Program for Windows 95/98/NT", Nucleic Acids Symposium Series, 41(pp. 95-98.
26. Huang, G.H. and W.B. Xu (2013), "[Recent advance in new types of human adenovirus]", Bing Du Xue Bao, 29(3): pp. 342-8.
27. Jin, X.H., et al. (2006), "Molecular epidemiology of adenoviral conjunctivitis in Hanoi, Vietnam", Am J Ophthalmol, 142(6): pp. 1064-6.
28. Kyte, J. and R.F. Doolittle (1982), "A simple method for displaying the hydropathic character of a protein", J Mol Biol, 157(1): pp. 105-32.
29. Lewis, P.F., et al. (2009), "A community-based outbreak of severe respiratory illness caused by human adenovirus serotype 14", J Infect Dis, 199(10): pp. 1427-34.
30. Liu, H., et al. (2010), "Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks", Science, 329(5995): pp. 1038- 43.
31. Lu, Z.Z., et al. (2013), "Penton-dodecahedral particles trigger opening of intercellular junctions and facilitate viral spread during adenovirus serotype 3 infection of epithelial cells", PLoS Pathog, 9(10): pp. e1003718.
32. Lynch, J.P., 3rd and A.E. Kajon (2016), "Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention",
Semin Respir Crit Care Med, 37(4): pp. 586-602.
33. Madisch, I., et al. (2007), "Phylogenetic analysis and structural predictions of human adenovirus penton proteins as a basis for tissue-specific adenovirus vector design", J Virol, 81(15): pp. 8270-81.
34. Mahr, J.A. and L.R. Gooding (1999), "Immune evasion by adenoviruses",
Immunol Rev, 168(pp. 121-30.
35. Matsui, K., et al. (2008), "Monitoring of adenovirus from conjunctival scrapings in Japan during 2005--2006", J Med Virol, 80(6): pp. 997-1003.
36. Meyer-Rusenberg, B., et al. (2011), "Epidemic keratoconjunctivitis: the current situation and recommendations for prevention and treatment", Dtsch
Arztebl Int, 108(27): pp. 475-80.
37. Nemerow, G.R., P.L. Stewart, and V.S. Reddy (2012), "Structure of human adenovirus", Curr Opin Virol, 2(2): pp. 115-21.
38. O'Brien, T.P., et al. (2009), "Acute conjunctivitis: truth and misconceptions",
Curr Med Res Opin, 25(8): pp. 1953-61.
39. Onion, D., et al. (2007), "The CD4+ T-cell response to adenovirus is focused against conserved residues within the hexon protein", J Gen Virol, 88(Pt 9): pp. 2417-25.
40. Persson, B.D., et al. (2010), "Structure of the extracellular portion of CD46 provides insights into its interactions with complement proteins and pathogens", PLoS Pathog, 6(9): pp. e1001122.
41. Pichla-Gollon, S.L., et al. (2007), "Structure-based identification of a major neutralizing site in an adenovirus hexon", J Virol, 81(4): pp. 1680-9.
42. Pommie, C., et al. (2004), "IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties", J Mol Recognit,
17(1): pp. 17-32.
43. Richards, A. and J.A. Guzman-Cottrill (2010), "Conjunctivitis", Pediatr Rev, 31(5): pp. 196-208.
44. Risch, N. and K. Merikangas (1996), "The future of genetic studies of complex human diseases", Science, 273(5281): pp. 1516-7.
45. Roelvink, P.W., et al. (1998), "The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F", J Virol, 72(10): pp. 7909-15.
46. Rose, P.W., et al. (2005), "Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo- controlled trial", Lancet, 366(9479): pp. 37-43.
47. Roy, S., et al. (1998), "Circumvention of immunity to the adenovirus major coat protein hexon", J Virol, 72(8): pp. 6875-9.
48. Rux, J.J., P.R. Kuser, and R.M. Burnett (2003), "Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods", J Virol, 77(17): pp. 9553-66.
49. Sambursky, R., et al. (2006), "The RPS adeno detector for diagnosing adenoviral conjunctivitis", Ophthalmology, 113(10): pp. 1758-64.
50. Sarantis, H., et al. (2004), "Comprehensive detection and serotyping of human adenoviruses by PCR and sequencing", J Clin Microbiol, 42(9): pp. 3963-9. 51. Segerman, A., et al. (2003), "Adenovirus type 11 uses CD46 as a cellular
receptor", J Virol, 77(17): pp. 9183-91.
52. Sheikh, A. and B. Hurwitz (2005), "Topical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis update", Br J Gen Pract, 55(521): pp. 962-4.
53. Singh-Naz, N. and W. Rodriguez (1996), "Adenoviral infections in children",
Adv Pediatr Infect Dis, 11(pp. 365-88.
54. Sirena, D., et al. (2004), "The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3", J Virol, 78(9): pp. 4454-62.
55. Smith, A.F. and C. Waycaster (2009), "Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States", BMC Ophthalmol, 9(pp. 13.
56. Szolajska, E., et al. (2012), "The structural basis for the integrity of adenovirus Ad3 dodecahedron", PLoS One, 7(9): pp. e46075.
57. Tischer, S., et al. (2016), "Discovery of immunodominant T-cell epitopes reveals penton protein as a second immunodominant target in human adenovirus infection", J Transl Med, 14(1): pp. 286.
58. Tomko, R.P., R. Xu, and L. Philipson (1997), "HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses", Proc Natl Acad Sci U S A, 94(7): pp. 3352-6.
59. Urry, L.A., et al.(2017), "Campbell biology", Eleventh edition. ed. New York, NY: Pearson Education, Inc.pp
60. Walls, T., A.G. Shankar, and D. Shingadia (2003), "Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients", Lancet Infect Dis, 3(2): pp. 79-86.
61. Walsh, M.P., et al. (2009), "Evidence of molecular evolution driven by recombination events influencing tropism in a novel human adenovirus that causes epidemic keratoconjunctivitis", PLoS One, 4(6): pp. e5635.
62. Waterhouse, A., et al. (2018), "SWISS-MODEL: homology modelling of protein structures and complexes", Nucleic Acids Res, 46(W1): pp. W296-
W303.
63. Waye, M.M.Y. and C.W. Sing (2010), "Anti-viral drugs for human adenoviruses", Pharmaceuticals, 3(10): pp. 3343-3354.
64. Wiethoff, C.M., et al. (2005), "Adenovirus protein VI mediates membrane disruption following capsid disassembly", J Virol, 79(4): pp. 1992-2000. 65. Wohlfart, C. (1988), "Neutralization of adenoviruses: kinetics, stoichiometry,
and mechanisms", J Virol, 62(7): pp. 2321-8.
66. Wold, W.S., T.W. Hermiston, and A.E. Tollefson (1994), "Adenovirus proteins that subvert host defenses", Trends Microbiol, 2(11): pp. 437-43. 67. Wood, S.R., et al. (1997), "Rapid detection and serotyping of adenovirus by
direct immunofluorescence", J Med Virol, 51(3): pp. 198-201.
68. Woodland, R.M., et al. (1992), "Causes of conjunctivitis and keratoconjunctivitis in Karachi, Pakistan", Trans R Soc Trop Med Hyg, 86(3): pp. 317-20.
69. Yabe, Y., et al. (1964), "Oncogenic Effect of Human Adenovirus Type 12, in Mice", Science, 143(3601): pp. 46-7.
70. Yabe, Y., J.J. Trentin, and G. Taylor (1962), "Cancer induction in hamsters by human type 12 adenovirus. Effect of age and of virus dose", Proc Soc Exp Biol
Med, 111(pp. 343-4.
71. Yu, X., et al. (2017), "Cryo-EM structure of human adenovirus D26 reveals the conservation of structural organization among human adenoviruses", Sci
Adv, 3(5): pp. e1602670.
72. Zubieta, C., et al. (2005), "The structure of the human adenovirus 2 penton",
Mol Cell, 17(1): pp. 121-35.
73. Ryder, E.C. and S. Benson, Conjunctivitis, in StatPearls. 2019: Treasure
Island (FL).
74. American-Optometric-Association. Conjunctivitis, www.aoa.org/patients- and-public/eye-and-vision-problems/glossary-of-eye-and-vision-
conditions/conjunctivitis, [cited 12 November, 2019].
75. Gompf, S.G. Adenovirus, https://emedicine.medscape.com/article/211738- overview, [cited 12 November, 2019].
76. Heiting, G. Pink eye: Symptoms and treatments,
www.allaboutvision.com/conditions/conjunctivitis.htm, [cited 12 November,
2019].
77. Human-Adenovirus-Working-Group. Human Adenovirus Genotype Classification, hadvwg.gmu.edu/, [cited 12 November, 2019].
78. Kozarsky, A. Conjunctivitis (Pinkeye), www.webmd.com/eye-health/eye- health-conjunctivitis#2, [cited 12 November, 2019].
79. SIB-Bioinformatics-Resource-Portal. Mastadenovirus,
viralzone.expasy.org/183?outline=all_by_species, [cited 12 November, 2019].
80. Soult, A. Amino acids,
https://chem.libretexts.org/Courses/University_of_Kentucky/UK%3A_CHE_ 103_-
_Chemistry_for_Allied_Health_(Soult)/Chapters/Chapter_13%3A_Amino_ Acids_and_Proteins/13.1%3A_Amino_Acids, [cited 19 November, 2019].
81. ThermoFisher. When Do I Use Sanger Sequencing vs NGS,
https://www.thermofisher.com/blog/behindthebench/when-do-i-use-sanger- sequencing-vs-ngs-seq-it-out-7/, [cited 3 January, 2019].
PHỤ LỤC - Trình tự gen fiber của HAdV-3 tại Việt Nam
ATGGCCAAGCGAGCTCGGCTAAGCACTTCCTTCAACCCGGTGTACCCTTATGA AGATGAAAGCAACTTACAACACCCATTTATAAATCCTGGTTTCATTTCCCCTGA CGGGTTCACACAAAGTCCAAACGGGGTTTTAAGTCTTAAATGTGTTAATCCACT TACCACTGCAAGCGGCTCCCTCCAACTTAAAGTGGGAAGTGGTCTTACAGTAG ACACTACTGATGGATCCTTAGAAGAAAACATCAAAGTTAACACCCCCCTAACA AAGTCAAACCATTCTATAAATTTACCAATAGGAAACGGTTTGCAAATAGAACA AAACAAACTTTGCAGTAAGCTCGGAAATGGTCTTACATTTGACTCTTCCAATTC TATTGCACTCAAAAATAACACTTTATGGACAGGTCCAAAACCAGAAGCCAACT GCATAATTGAATACGGGAAAGAAAACCCAGATAGCAAACTAACTTTAATCCTT GTAAAAAATGGAGGAATTGTTAATGGATATGTAACGCTAATGGGAGCCTCAGA CTATGTTAACACCTTATTTAAAAACAAAAATGTCTCCATTAATGTAGAATTATA CTTTGATGCCACTGGTCATATATTACCAGACTTATCTTCTCTTAAAACAGATCT ACAACTAAAATACAAGCAAACCACTCACTTTAGTGCAAGAGGTTTTATGCCAA GTACTACAGCGTATCCATTTGTCCTTCCTAATGCGGGAACAGATAATGAAAATT ATATTTTTGGTCAATGCTACTACAAAGCAAGCGATGGCGCCCTTTTTCCGTTGG AAGTTACTGTTACGCTTAATAAACGCCTGCCAGATAGTCGCACATCCTATGTTA TGACTTTTTTATGGTCCTTGAATGCTGGTCTAGCTCCAGAAACTACTCAGGCAA CCCTCATAACCTCCCCATTTACCTTTTCCTATATTACAGAAGATGACTGA
- Trình tự protein fiber của HAdV-3 tại Việt Nam
MAKRARLSTSFNPVYPYEDESNLQHPFINPGFISPDGFTQSPNGVLSLKCVNPLTTA SGSLQLKVGSGLTVDTTDGSLEENIKVNTPLTKSNHSINLPIGNGLQIEQNKLCSKL GNGLTFDSSNSIALKNNTLWTGPKPEANCIIEYGKENPDSKLTLILVKNGGIVNGYV TLMGASDYVNTLFKNKNVSINVELYFDATGHILPDLSSLKTDLQLKYKQTTHFSAR GFMPSTTAYPFVLPNAGTDNENYIFGQCYYKASDGALFPLEVTVTLNKRLPDSRTS YVMTFLWSLNAGLAPETTQATLITSPFTFSYITEDD
- Trình tự gen penton của HAdV-3 tại Việt Nam
ATGAGGAGACGAGCCGTGCTAGGCGGAGCGGTGGTGTATCCGGAGGGTCCTCC TCCTTCTTACGAGAGCGTGATGCAGCAACAGGCGGCGATGCTACAGCCCCCAC TGGAGGCTCCCTTCGTACCCCCGCGGTACCTGGCGCCTACGGAAGGGAGAAAC AGCATTCGTTACTCGGAGCTGTCGCCCCTGTACGATACCACCAAGTTGTATCTG GTGGACAACAAGTCGGCGGACATTGCCTCCCTGAACTATCAGAACGACCACAG CAACTTCCTGACCACGGTGGTGCAGAACAATGACTTTACCCCCACGGAGGCTA GCACCCAGACCATCAACTTTGACGAGCGGTCGCGATGGGGCGGTCAGCTGAAG
ACCATCATGCACACCAACATGCCCAACGTGAACGAGTACATGTTCAGCAACAA GTTCAAGGCGAGGGTGATGGTGTCCAGAAAGGCTCCTGAAGGTGTTATAGTAA ATGACACCTATGATCATAAAGAGGATATCTTAAAGTATGAGTGGTTTGAGTTC ACTTTACCAGAAGGCAACTTCTCAGCCACCATGACCATTGACCTGATGAACAA TGCCATCATTGACAACTACCTGGAAATTGGCAGACAAAATGGAGTGCTGGAAA GTGACATTGGTGTTAAGTTTGACACTAGAAACTTTAGGCTCGGGTGGGACCCC GAAACTAAGTTGATTATGCCAGGAGTCTACACTTATGAGGCATTCCATCCTGA CATTGTTTTGCTGCCTGGTTGCGGGGTAGACTTTACTGAAAGCCGACTTAGCAA CTTGCTTGGCATCAGGAAAAGACATCCATTCCAGGAGGGTTTCAAAATTATGT ATGAAGATCTTGAAGGGGGTAATATTCCTGCCCTTTTGGATGTCACTGCCTATG AGGAAAGCAAAAAGGATACCACTACTGAAACAACCACACTGGCTGTTGCAGA GGAAACTAGTGAAGATGATAATATAACTAGAGGAGATACTTATATAACTGAAA AACAAAAACGTGAAGCTGCAGCTGCTGAAGTTAAAAAAGAGTTAAAGATCCA ACCTCTAGAAAAAGACAGCAAGAGTAGAAGCTACAATGTCTTGGAAGACAAA ATCAACACGGCCTACCGCAGCTGGTACCTGTCCTACAATTACGGTAACCCCGA GAAAGGAATAAGGTCTTGGACACTGCTTACCACTTCAGATGTCACCTGTGGGG CAGAGCAGGTCTACTGGTCGCTCCCTGACATGATGCAAGACCCAGTCACCTTC CGCTCCACAAGACAAGTCAACAACTACCCAGTGGTGGGTGCAGAGCTTATGCC CGTCTTCTCAAAGAGTTTCTACAATGAGCAAGCCGTGTACTCTCAGCAGCTCCG ACAGACCACTTCGCTCACGCACGTCTTCAACCGCTTCCCTGAGAACCAGATCCT CATCCGCCCGCCGGCGCCCACAATTACCACCGTCAGTGAAAACGTTCCTGCTC TCACAGATCACGGGACCCTGCCGTTACGCAGCAGTATCCGGGGAGTCCAGCGC GTGACCGTTACTGACGCCAGACGCCGCACCTGTCCCTACGTTTACAAGGCCCT GGGCATAGTCGCGCCGCGCGTTCTTTCAAGCCGCACTTTCTAA
- Trình tự protein penton của HAdV-3 tại Việt Nam
MRRRAVLGGAVVYPEGPPPSYESVMQQQAAMLQPPLEAPFVPPRYLAPTEGRNSI RYSELSPLYDTTKLYLVDNKSADIASLNYQNDHSNFLTTVVQNNDFTPTEASTQTI NFDERSRWGGQLKTIMHTNMPNVNEYMFSNKFKARVMVSRKAPEGVIVNDTYD HKEDILKYEWFEFTLPEGNFSATMTIDLMNNAIIDNYLEIGRQNGVLESDIGVKFDT RNFRLGWDPETKLIMPGVYTYEAFHPDIVLLPGCGVDFTESRLSNLLGIRKRHPFQ EGFKIMYEDLEGGNIPALLDVTAYEESKKDTTTETTTLAVAEETSEDDNITRGDTYI TEKQKREAAAAEVKKELKIQPLEKDSKSRSYNVLEDKINTAYRSWYLSYNYGNPE KGIRSWTLLTTSDVTCGAEQVYWSLPDMMQDPVTFRSTRQVNNYPVVGAELMPV FSKSFYNEQAVYSQQLRQTTSLTHVFNRFPENQILIRPPAPTITTVSENVPALTDHGT LPLRSSIRGVQRVTVTDARRRTCPYVYKALGIVAPRVLSSRTF
- Trình tự gen hexon của HAdV-3 tại Việt Nam ATGGCCACCCCATCGATGATGCCCCAATGGGCATACATGCACATCGCCGGACA GGATGCTTCGGAGTACCTGAGTCCGGGTCTGGTGCAGTTCGCCCGTGCAACAG ACACCTACTTCAGTATGGCGAACAAATTTAGAAACCCCACAGTGGCGCCCACC CACGATGTGACCACCGATCGTAGCCAGCGCCTGATGCTGCGCTTCGTGCCCGT TGACCGGGAAGACAATACCTACTCTTACAAAGTTCGCTACACGCTGGCTGTAG GCGACAACAGAGTGCTTGACATGGCCAGCACATTCTTTGACATTCGGGGGGTG CTTGATAGAGGTCCTAGCTTCAAGCCATATTCCGGCACAGCTTACAATTCACTC GCTCCTAAGGGCGCGCCCAATACATCTCAGTGGATAGTTACAACGAATCGAGA CAATGCAGTAACTACCACCACAAACACATTTGGCATTGCTTCCATGAAGGGAG ACAATATTACTAAAGAAGGTTTGCAAATTGGGAAAGACATTACCACTACTGAA GGAGAAGAAAAGCCCATTTATGCCGATAAAACATATCAGCCAGAGCCTCAAGT TGGAGAAGAATCATGGACTGATACTGATGGAACAAATGAAAAGTTTGGTGGA AGAGCCCTTAAACCAGCTACCAACATGAAGCCATGCTACGGGTCTTTTGCAAG ACCTACAAACATAAAAGGGGGCCAAGCTAAAAACAGAAAAGTAAAACCAACA ACCGAAGGAGGGGTTGAAACTGAGGAACCAGATATTGATATGGAATTTTTCGA TGGTAGAGATGCTGTTGCAGGAGCTTTAGCGCCTGAAATTGTGCTTTATACGG AAAATGTAAATTTGGAAACTCCAGACAGTCATGTGGTATATAAACCAGGAACG TCTGATAACTCTCATGCAAATTTGGGTCAACAAGCCATGCCTAACAGACCCAA TTACATTGGATTCAGGGATAACTTTGTAGGCCTAATGTACTACAACAGTACTGG AAATATGGGAGTTTTGGCTGGCCAAGCATCACAACTGAATGCAGTGGTTGACT TGCAGGACAGAAATACTGAACTGTCATATCAGCTTTTGCTTGATTCTCTGGGAG ACAGAACCAGATACTTCAGCATGTGGAATCAGGCTGTGGACAGTTACGATCCC GATGTTCGCATTATTGAAAATCATGGCATCGAGGATGAACTGCCTAATTACTGT TTTCCTCTGGATGGCATAGGACCAGGGCACAGGTATCAAGGCATTAAAGTTAA AACCGATGACGCTAATGGATGGGAAAAAGATGCTAATGTTGATACAGCTAATG AAATAGCCATAGGAAACAACCTGGCTATGGAAATTAATATCCAAGCTAACCTT TGGAGAAGTTTTCTGTACTCCAATGTGGCTTTGTACCTTCCAGATGTTTACAAG TACACGCCACCTAACATTACTTTGCCCACTAACACCAACACCTATGAGTACAT GAACGGGCGAGTGGTATCCCCATCTCTGGTTGATTCATACATCAACATCGGCG CCAGGTGGTCTCTTGACCCAATGGACAATGTGAATCCATTCAACCACCACCGC AATGCTGGTCTGCGCTACAGGTCCATGCTTCTGGGAAATGGTCGTTATGTGCCT TTCCACATACAAGTGCCTCAAAAATTCTTTGCTGTCAAAAACCTACTTCTTCTA CCTGGCTCCTACACCTACGAGTGGAACTTCAGAAAGGATGTGAACATGGTCCT GCAAAGTTCCCTTGGAAATGACCTCAGAACAGATGGTGCTACCATAAGTTTCA CCAGCATCAATCTCTATGCCACCTTCTTCCCCATGGCTCACAACACAGCTTCCA CCCTTGAAGCCATGCTGCGCAACGATACCAATGATCAGTCATTTAACGACTAC
CTCTCTGCAGCTAACATGCTTTACCCCATTCCTGCCAATGCAACCAACATTCCA ATTTCCATCCCATCTCGCAACTGGGCAGCCTTCAGGGGCTGGTCCTTCACCAGG CTCAAAACCAAGGAGACTCCATCTCTTGGATCAGGGTTCGATCCCTACTTCGTA TATTCTGGATCTATTCCCTACCTGGATGGCACCTTCTACCTTAACCACACTTTCA AGAAGGTCTCCATCATGTTTGACTCCTCAGTCAGCTGGCCTGGCAATGACAGG CTGTTGAGCCCAAATGAGTTTGAAATCAAGCGCACTGTGGACGGGGAAGGATA CAACGTGGCACAATGCAACATGACCAAAGACTGGTTCCTAGTTCAGATGCTTG CCAACTACAACATTGGCTACCAGGGCTTTTACATCCCTGAGGGATACAAGGAT CGCATGTACTCCTTTTTCAGAAACTTCCAGCCTATGAGCAGGCAGGTGGTTGAT GAGGTTAATTACACTGACTACAAAGCCGTCACCTTACCATATCAACACAACAA CTCTGGCTTTGTAGGATACCTTGCGCCTACTATGAGACAAGGGGAACCTTACCC AGCCAATTATCCATACCCGCTCATCGGAACTACTGCCGTTAAAAGTGTTACCCA AAAAAAGTTCCTGTGCGACAGGACCATGTGGCGCATACCGTTCTCCAGCAACT TCATGTCCATGGGAGCCCTTACGGACCTGGGACAGAACCTGCTCTATGCCAAC TCGGCCCATGCGCTGGACATGACTTTTGAGGTGGATCCCATGGATGAGCCCAC CCTGCTTTATCTTCTTTTCGAAGTCTTCGACGTGGTCAGAGTGCACCAGCCACA CCGCGGCGTCATCGAGGCCGTCTACCTGCGCACACCGTTCTCGGCCGGCAACG CCACCACATAA
- Trình tự protein hexon của HAdV-3 tại Việt Nam
MATPSMMPQWAYMHIAGQDASEYLSPGLVQFARATDTYFSMANKFRNPTVAPT HDVTTDRSQRLMLRFVPVDREDNTYSYKVRYTLAVGDNRVLDMASTFFDIRGVL DRGPSFKPYSGTAYNSLAPKGAPNTSQWIVTTNRDNAVTTTTNTFGIASMKGDNIT KEGLQIGKDITTTEGEEKPIYADKTYQPEPQVGEESWTDTDGTNEKFGGRALKPAT NMKPCYGSFARPTNIKGGQAKNRKVKPTTEGGVETEEPDIDMEFFDGRDAVAGA LAPEIVLYTENVNLETPDSHVVYKPGTSDNSHANLGQQAMPNRPNYIGFRDNFVG LMYYNSTGNMGVLAGQASQLNAVVDLQDRNTELSYQLLLDSLGDRTRYFSMWN QAVDSYDPDVRIIENHGIEDELPNYCFPLDGIGPGHRYQGIKVKTDDANGWEKDA NVDTANEIAIGNNLAMEINIQANLWRSFLYSNVALYLPDVYKYTPPNITLPTNTNT YEYMNGRVVSPSLVDSYINIGARWSLDPMDNVNPFNHHRNAGLRYRSMLLGNGR YVPFHIQVPQKFFAVKNLLLLPGSYTYEWNFRKDVNMVLQSSLGNDLRTDGATIS FTSINLYATFFPMAHNTASTLEAMLRNDTNDQSFNDYLSAANMLYPIPANATNIPIS IPSRNWAAFRGWSFTRLKTKETPSLGSGFDPYFVYSGSIPYLDGTFYLNHTFKKVSI MFDSSVSWPGNDRLLSPNEFEIKRTVDGEGYNVAQCNMTKDWFLVQMLANYNIG YQGFYIPEGYKDRMYSFFRNFQPMSRQVVDEVNYTDYKAVTLPYQHNNSGFVGY LAPTMRQGEPYPANYPYPLIGTTAVKSVTQKKFLCDRTMWRIPFSSNFMSMGALT DLGQNLLYANSAHALDMTFEVDPMDEPTLLYLLFEVFDVVRVHQPHRGVIEAVY LRTPFSAGNATT